Two PPARδ Agonists, One Research Question
GW0742 and GW501516 are structurally related PPARδ agonists that share a common research heritage and overlapping mechanistic profiles, but differ in ways that matter when selecting a tool compound. Both were developed from the same GlaxoSmithKline chemical series and produce similar metabolic effects — fatty acid oxidation, endurance enhancement in rodents, anti-inflammatory signaling, and lipid profile improvement. The key practical differences relate to potency, selectivity, and published safety data.
Potency and Selectivity Differences
GW0742 has a higher binding affinity for PPARδ than GW501516 (reported EC50 of ~1 nM vs ~4 nM in cell-based assays). It is also more selective for PPARδ over PPARα and PPARγ, which has made it useful in studies designed to isolate PPARδ-specific effects from pan-PPAR signaling. GW501516 activates PPARδ primarily but has some activity at other PPAR subtypes at higher concentrations, adding a variable to designs where subtype specificity matters.
Safety Profile Considerations
GW501516’s development was halted after multi-dose rodent carcinogenicity studies showed rapid tumor formation across multiple tissue types. GW0742 has a more limited published safety dataset, but has not been associated with the same dramatic carcinogenicity findings in standard research publications. For this reason, some researchers working with PPARδ biology prefer GW0742 when GW501516’s risk profile is a concern — though both require appropriate institutional oversight and safety protocols.
Research Applications for Each
GW501516 is preferred when robust published dose-response data and cross-study comparability are priorities. GW0742 is preferred for higher-specificity PPARδ research, cardiovascular models (particularly pulmonary hypertension and cardiac metabolism studies), and neuroprotection studies. Both compounds are often studied alongside Rev-ErbA agonists like SR9009 and SR9011 in metabolic panel studies. For anabolic/metabolic combination designs, SARMs like Ostarine or RAD-140 are frequently added alongside either PPARδ agonist.
Products Available
- GW0742 Solution (10mg/ml – 50ml)
- GW501516 | Cardarine Solution (10mg/ml – 50ml)
- Cardarine GW-501516 Powder (1g)
See our full GW501516 Research Guide. For laboratory research use only.
